DENNIS SLONE, M.D.; SAMUEL SHAPIRO, M.B.; OLLI S. MIETTINEN, M.D.; WILLIAM D. FINKLE, Ph.D.; PAUL D. STOLLEY, M.D.
▸Requests for reprints should be addressed to Dennis Slone, M.D.; Drug Epidemiology Unit, 10 Moulton Street; Cambridge, MA 02138.
SLONE D, SHAPIRO S, MIETTINEN OS, FINKLE WD, STOLLEY PD. Drug Evaluation After Marketing. Ann Intern Med. 1979;90:257-261. doi: 10.7326/0003-4819-90-2-257
Download citation file:
Published: Ann Intern Med. 1979;90(2):257-261.
After marketing, drugs should be evaluated for safety and for efficacy. Present national systems are inadequate for both tasks. Safety can be evaluated by means of nonexperimental research, whereas evaluation of efficacy in a variety of settings representing normal medical practice generally requires experiments, randomized and blinded. Research into safety requires the maintenance of routine, yet flexible, multipurpose data systems, different for established and newly marketed drugs. Ad hoc studies on safety and on efficacy can be mounted more swiftly and economically through the maintenance of "standby" capabilities, in addition to maximal use of resources outside the actual national system.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only